摘要
目的评价血脂康联合瑞舒伐他汀对于高脂血症患者血脂与炎性因子水平的影响。方法选择2019年10月至2022年9月间宜兴市中医医院收治的269例高脂血症患者,随机分为瑞舒伐他汀组(90例)、血脂康组(89例)、联合组(90例),瑞舒伐他汀组使用瑞舒伐他汀治疗,血脂康组使用血脂康治疗,联合组联用瑞舒伐他汀和血脂康治疗,6个月后对比两组患者的血脂水平、炎性因子水平、不良反应。结果联合组的总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)均低于其他两组,高密度脂蛋白胆固醇(HDL-C)高于其他两组(P<0.05);瑞舒伐他汀组与血脂康组的4项血脂指标比较,差异无统计学意义(P>0.05)。联合组的C反应蛋白(CRP)、磷酸肌酸激酶同工酶(CK-MB)均显著低于其他两组(P<0.05);瑞舒伐他汀组与血脂康组的2项炎性因子指标比较,差异无统计学意义(P>0.05)。不良反应发生率血脂康组为4.49%(4/89)、联合组为5.56%(5/90),均显著低于瑞舒伐他汀组14.44%(13/90)(P<0.05)。结论血脂康联合瑞舒伐他汀,有利于降低高脂血症患者的血脂水平,缓解炎症情况,并且减少不良反应,具有较高的推广应用价值。
Objective To analyze the effect of xuezhikang combined with rosuvastatin on blood lipid level and inflammatory factors in patients with hyperlipidemia.Methods A total of 269 patients with hyperlipidemia admitted to Yixing Traditional Chinese Medicine Hospital from October 2019 to September 2022 were randomly divided into rosuvastatin group(90 cases),xuezhikang group(89 cases)and combined group(90 cases).Rosuvastatin group was treated with rosuvastatin,xuezhikang group was treated with xuezhikang,combined group was treated with rosuvastatin and xuezhikang.After 6 months,the blood lipid level,inflammatory factor level and adverse reactions of the two groups were compared.Results The TC,LDL-C,and TG of patients in the combination group were lower than those in the other two groups,while HDL-C was higher than those in the other two groups,with a statistically significant difference(P<0.05);there was no significant difference in four blood lipid indexes between rosuvastatin group and xuezhikang group(P>0.05).The CRP and CK-MB of patients in the combined group were significantly lower than those in the other two groups(P<0.05).there was no significant difference between the two inflammatory factor indexes of rosuvastatin group and xuezhikang group(P>0.05).The incidence of adverse reactions in xuezhikang group was 4.49%(4/89),and that in combination group was 5.56%(5/90),which were significantly lower than that in rosuvastatin group 14.44%(13/90)(P<0.05).Conclusion Xuezhikang combined with rosuvastatin can reduce the blood lipid level,alleviate inflammation and reduce adverse reactions in patients with hyperlipidemia.
作者
强双畅
史淋峰
史静艳
QIANG Shuangchang;SHI Linfeng;SHI Jingyan(Yixing Traditional Chinese Medicine Hospital,Yixing Jiangsu 214200,China)
出处
《药品评价》
CAS
2023年第10期1229-1232,共4页
Drug Evaluation
关键词
高脂血症
血脂康
瑞舒伐他汀
血脂
炎性因子
影响
Hyperlipidemias
Xuezhikang
Rosuvastatin
Blood lipid
Inflammatory factors
Effect
